AvKARE Recalls Valsartan Tablets Due to Carcinogen Impurity in API
AvKARE, Inc. is recalling specific lots of Valsartan Tablets 160 mg because a carcinogen impurity was detected in the active pharmaceutical ingredient used to manufacture the drug.
- Product
- Valsartan Tablets, USP 160 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-785-15 Manufactured for: AvKARE, Inc. Pulaski, TN 38478
- Category
- Drug
- Distribution
- Distributed nationwide